EFTRW - eFFECTOR Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.1520
+0.0220 (+16.92%)
At close: 03:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1300
Open0.1500
Bid0.1310 x 1100
Ask0.9000 x 900
Day's Range0.1262 - 0.1758
52 Week Range0.1262 - 0.1758
Volume11,812
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for EFTRW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase p

    • GlobeNewswire

      eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

      Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated populationPartial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet)Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2Company will host a virtual investor call on June 4, 2023, to discuss the data and clinical pro

    • GlobeNewswire

      eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients with ER+, human epidermal growth factor receptor 2-negative (HER2-) brea

    • GlobeNewswire

      eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of t

    • GlobeNewswire

      eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting

      eFFECTOR to host conference call following ASCO presentationSOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been sel

    • GlobeNewswire

      eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

      The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk patients carrying specific markers predictive of relapseSOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a clinical collaboration with Jennife

    • GlobeNewswire

      eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Fireside Chat at Cantor’s the Future of Oncology Virtual Symposium on April 3, 2023 at 11am ETFireside Chat at Stifel’s Targeted O

    • GlobeNewswire

      eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is anticipated in first half of 2023 Topline data for Phase 2b KICKSTART trial in NSCLC anticipated in second half of 2023 Cash runway anticipated into first quarter of 2024 SOLANA BEACH and REDWOOD CITY

    • GlobeNewswire

      eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

      Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced top-line results from its Phase 1b clinical trial of zotatifin for the treatment of COVID demonstrating favorable safety results as well as positive trends in s

    • GlobeNewswire

      eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

      SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company

    • GlobeNewswire

      eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

      Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial with tomivosertib in non-small cell lung cancer Management to present results and provide full pipeline update in investor call on January 5, 2023 at 4:30 p.m. ET SOLANA BEACH, Calif. and REDWOOD CITY,

    • GlobeNewswire

      eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      - Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second cohort of Phase 1b clinical trial of zotatifin for the treatment of COVID-19 - SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a lea

    • GlobeNewswire

      eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

      Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023SAN DIEGO and REDWOOD CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults w

    • GlobeNewswire

      eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

      SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR’s corporate growth strategy, business development and partnership opportunities. “Mayank is an accomplished leader with extensive experience in the biopharmac

    • GlobeNewswire

      eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

      - Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1x1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference. Panel Topic:“Building Combinations:

    • GlobeNewswire

      eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

      - Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 - - Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation - SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the se

    • GlobeNewswire

      eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

      SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. Presentation Date:Monday, September 12, 2022Time:9:30 AM ETPresenter:Steve Worland, Ph.D., President and Chief Executive OfficerPres

    • GlobeNewswire

      eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD CITY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate up

    • GlobeNewswire

      eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

      SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer. Dr. Warner will develop strategies to continue advancing eFFECTOR’s two clinical-stage STRIs into advanced and potentially registrational trials. “Dr. Warner has extensive experience in oncolo

    • GlobeNewswire

      eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

      Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer patients with Cyclin D amplification Management and key opinion leaders to present results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: